Salix Pharmaceuticals Ltd

Salix Pharmaceuticals — Investor Presentation (January 2008)

29 slides from Salix Pharmaceuticals's investor presentation, Jan 31, 2008

  1. Slide 1: Salix Pharmaceuticals, Ltd. - The Name Gastroenterologists Trust

    Salix Pharmaceuticals, Ltd. The Name Gastroenterologists Trust Exhibit 99.2

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement Statements presented in this overview that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from projected results. Factors that could cause actual results to differ materially

  3. Slide 3: Generic Balsalazide

    Generic Balsalazide December 28, 2007 Office of Generic Drugs Approved 3 Generic Balsalazide Products Salix Announced Watson Authorized Generic

  4. Slide 4: Current Situation

    Current Situation • Dramatic price erosion for COLAZAL – $125 million COLAZAL market now a $30-42 million balsalazide market • Impact on price of future IBD products – Balsalazide tablet and granulated mesalamine • Substantial non-cash charge in 4Q07 • Not profitable in 2008 – Financial guidance to

  5. Slide 5: Future Outlook

    Future Outlook • Based on current projections – – No need to raise money to execute business plan – Sufficient cash reserve to return to profitability • Expect to be cash flow positive in 2009 • OSMOPREP and MOVIPREP well-positioned in a growing market – TRx market growth of 18% in 2007* – Osmoprep/

  6. Slide 6: Future Outlook

    Future Outlook • 3 NDA approvals anticipated in 2008 – Balsalazide tab, granulated mesalamine, and metoclopramide-ZYDIS • Focus 2008 R&D spend on largest potential indications • Rifaximin Irritable Bowel Syndrome (IBS) program – Mid-2008: Initiate Phase III trials – 2008: Publication/presentation of

  7. Slide 7: Mission Statement

    Mission Statement Salix Pharmaceuticals is committed to being the leading U.S. specialty pharmaceutical company licensing, developing and marketing innovative products to health care professionals to prevent or treat gastrointestinal disorders.

  8. Slide 8: Strategy

    Strategy • In-license selective late-stage/marketed product candidates – U.S. gastroenterology focus – Reduce risk and capital commitment • Complete development and secure FDA approval • Sell products through specialty sales force – Establish franchise with U.S. gastroenterologists – Sell products t

  9. Slide 9: An Overall Compelling Market Opportunity

    An Overall Compelling Market Opportunity • An influential and demanding target audience (13,400 specialty physicians) – 30.5 million patient visits annually – 40 million prescriptions annually – $6 billion Rx sales annually Source: Verispan PDDA and Wolters Kluwer Health (1/08)

  10. Slide 10: History of Success

    History of Success 2007 2006 2005 2004 2003 2002 2001 2000 Product Launches NDA Approvals Metoclopramide- ZYDIS ® Vapreotide acetate Granulated Mesalamine Acquisitions

  11. Slide 11: Anticipated Approvals

    Anticipated Approvals • INFLAMMATORY BOWEL DISEASE – Balsalazide tablet (1100 mg) 2Q08 – Granulated mesalamine (1.5 gm) 4Q08 • METOCLOPRAMIDE-ZYDIS 4Q08 • RIFAXIMIN – Hepatic Encephalopathy (550 mg) 3Q09 – Irritable Bowel Syndrome (550 mg) Mid-2011

  12. Slide 12: Xifaxan (rifaximin) tablets - Targeted GI Antibiotic

    NONSYSTEMIC Xifaxan (rifaximin) tablets 200 mg TARGETED GI ANTIBIOTIC

  13. Slide 13: Xifaxan

    Xifaxan • Unique, Gastrointestinal-Specific Antibiotic – Broad spectrum – Reduced risks – No stable resistance • 2004 FDA approval for treatment of travelers’ diarrhea • Patent coverage: May 24, 2024* – Orange Book listed *Patent expiration dates listed herein are for US patents and assume there are

  14. Slide 14: Slide 14

  15. Slide 15: Slide 15

  16. Slide 16: Slide 16

  17. Slide 17: Rifaximin Intellectual Property

    RIFAXIMIN Intellectual Property RIFAXIMIN 550mg (HE) RIFAXIMIN 550mg (IBS) XIFAXAN 200mg (TD) Polymorphous forms of RIFAXIMAN, processes for their production and use thereof in medicinal preparations Q2 2011 Q1 2009 Q3 2009 Q2 2010 3-28-11 HE anticipated filing 7 year orphan exclusivity HE anticipat

  18. Slide 18: MoviPrep and OsmoPrep products

    ©smor 7 nonas| ie monohydrate im phosphate dibasic arhycrus, USP Tablets Reliable elas Tablets MoviPrep (PEG-3360, Sodium Sufate Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution) Low-Volume Prep. High-Volume Efficacy.

  19. Slide 19: Improved Preps for Colonoscopy

    Improved Preps for Colonoscopy • OsmoPrep Proprietary tablet formulation Launched June 2006 Patent coverage: May 2013* • MoviPrep Proprietary, state-of-the-art 2 liter liquid PEG with ascorbic acid Launched October 2006 Patent coverage: September 2024* • Bowel Prep TRx Market Growth in 2007 Total ma

  20. Slide 20: Next Generation IBD Products

    Next Generation IBD Products • Balsalazide Tablet (1100mg) PDUFA* action date – May 16, 2008 Patent coverage: March 2018** Expected launch July 2008 • Granulated Mesalamine (375mg capsule) PDUFA action date – 4Q08 (estimate) Patent coverage: April 2018** Expected launch Jan/Feb 2009 *Prescription Dr

  21. Slide 21: Products in Development

    Products in Development • Metoclopramide-ZYDIS ® Gastroparesis/Gastroesophageal reflux Expected approval 4Q08 Expected launch Jan/Feb 2009 Patent coverage: July 2017* • Vapreotide acetate Treatment of acute esophageal variceal bleeding » Serious complication of late-stage liver cirrhosis – Ongoing c

  22. Slide 22: Capitalization – 9/30/07

    Capitalization – 9/30/07 (in millions) Actual 48.6 Fully diluted common shares (Treasury method) 47.2 Common shares outstanding $15.0 Long term debt $70.2 Cash, cash equivalents & investments

  23. Slide 23: Current Run Rates for Base Business

    Current Run Rates for Base Business Revenue Run Rate (in millions)* ~ $28 Other Products ~$5** Colazal ~ $60 MoviPrep OsmoPrep Visicol ~ $64 Xifaxan (rifaximin) *Run rate based on current Rx data **Estimate for 2008

  24. Slide 24: Slide 24

  25. Slide 25: Slide 25

  26. Slide 26: Slide 26

  27. Slide 27: 2008 Anticipated Milestones

    2008 Anticipated Milestones Q2 2008 Q1 2008 • Complete Rifaximin HE Phase III enrollment • Balsalazide tablet PDUFA action date • Digestive Disease Week – Rifaximin IBS Phase IIb data and balsalazide tablet data (abstracts submitted) • Initiate Rifaximin IBS Phase III trials (Mid-2008) Q3 2008 • Lau

  28. Slide 28: 2009 Anticipated Milestones

    2009 Anticipated Milestones • File Rifaximin HE NDA (4Q08/1Q09) • Launch granulated mesalamine • Launch metoclopramide-ZYDIS • Compete Rifaximin IBS Phase III enrollment • Expect to be cash flow positive

  29. Slide 29: Salix Pharmaceuticals, Ltd. - The Gastroenterology Company

    Salix Pharmaceuticals, Ltd. The Gastroenterology Company Providing products to gastroenterologists and their patients

Salix Pharmaceuticals — Investor Presentation (January 2008) on 6ix